| |
Buspirone HCI is indicated for the management of anxiety disorders
of the short-term relief of anxiety. Is is the generic form of BuSpar.
Buspirone Hydrochloride is indicated for the management of anxiety
disorders or the short-term relief of the symptoms of anxiety. It
is an agent that is not chemically or pharmacologically related
to the benzodiazepines (e.g. Valium, Xanax) barbituates, or other
sedative/anti-anxiety drugs. Buspirone tablets come in 5mg, 10mg,
15mg and 30mg strengths.
| DRUG |
DOSAGE |
QUANTITY |
CONSULT |
PRICES |
|
 |
|
| Buspirone |
5mg |
30 tabs |
FREE |
CALL
|
Order |
|
Buspirone |
5mg |
90 tabs |
FREE |
CALL
|
Order |
| Buspirone |
10mg |
30 tabs |
FREE |
CALL
|
Order |
|
Buspirone |
10mg |
90 tabs |
FREE |
CALL
|
Order |
|
 HOW
DOES BUSPAR WORK?
The mechanism of action of BUSPAR is not clearly known.
BUSPAR differs from typical benzodiazepines like Vallium or Xanax
anti-anxiety medication in that it does not exert anti-seizure or
muscle relaxant effects. It also lacks the prominent sedative effect
that is associated with benzodiazepines.
In vitro studies have shown that BUSPAR has a high affinity for
serotonin receptors (receptors in the brain that mediate arousal).
BUSPAR has no significant affinity for benzodiazepine receptors
in the brain.
Top
HOW EFFECTIVE IS BUSPAR?
The excellent efficacy of BUSPAR has been demonstrated in controlled
clinical trials of outpatients with a diagnosis of Generalized Anxiety
Disorder (GAD).
The patients evaluated in these studies had experienced symptoms
for periods of 1 month to over 1 year prior to the study, with an
average symptom duration of 6 months. Generalized, persistent anxiety
(of at least one month continual duration), manifested by symptoms
from three of the four following categories:
Motor tension: Shakiness, jitteriness, jumpiness, trembling, tension,
muscle aches, fatigability, inability to relax, eyelid twitch, furrowed
brow, strained face, fidgeting, restlessness, easy startle.
Autonomic hyperactivity: Sweating, heart pounding or racing, cold,
clammy hands, dry mouth, dizziness, lightheadedness, paresthesias
(tingling in hands or feet), upset stomach, hot or cold spells,
frequent urination, diarrhea, discomfort in the pit of the stomach,
lump in the throat, flushing, pallor, high resting pulse and respiration
rate.
Apprehensive expectation: Anxiety, worry, fear, rumination, and
anticipation of misfortune to self or others.
Vigilance and scanning: Hyper-attentiveness resulting in distractibility,
difficulty in concentrating, insomnia, feeling "on edge",
irritability, impatience.
The effectiveness of BUSPAR in long-term use, that is, for more
than 3 to 4 weeks, has not been demonstrated in controlled trials.
There is no body of evidence available that systematically addresses
the appropriate duration of treatment for GAD. However, in a study
of long-term use, 264 patients were treated with BUSPAR for 1 year
without ill effect. Therefore, the physician who elects to use BUSPAR
for extended periods should periodically reassess the usefulness
of the drug for the individual patient.
Top
DOSAGE AND ADMINISTRATION:
The recommended initial dose is 15 mg daily (5 mg 3 times a day).
To achieve an optimal therapeutic response, at intervals of 2 to
3 days the dosage may be increased 5 mg per day, as needed. The
maximum daily dosage should not exceed 60 mg per day. In clinical
trials allowing dose titration, divided doses of 20 to 30 mg per
day were commonly employed.
Top
ADVERSE REACTIONS:
The more commonly observed untoward events associated with the use
of BUSPAR not seen at an equivalent incidence among placebo-treated
patients include dizziness, nausea, headache, nervousness, lightheadedness,
and excitement.
Other common adverse events included: central nervous system disturbances
(3.4%), primarily dizziness, insomnia, nervousness, drowsiness,
and lightheaded feeling; gastrointestinal disturbances (1.2%), primarily
nausea; and miscellaneous disturbances (1.1%), primarily headache
and fatigue.
Interference with cognitive and motor performance: Studies indicate
that BUSPAR is less sedating than other anti-anxiety medications
and that it does not produce significant functional impairment.
However, its CNS effects in any individual patient may not be predictable.
Therefore, patients should be cautioned about operating an automobile
or using complex machinery until they are reasonably certain that
BUSPAR treatment does not affect them adversely.
While formal studies of the interaction of BUSPAR with alcohol indicate
that BUSPAR does not increase alcohol-induced impairment in motor
and mental performance, it is prudent to avoid concomitant use of
alcohol and BUSPAR.
Top
DRUG ABUSE AND DEPENDENCE:
In human and animal studies, BUSPAR has shown no potential for abuse
or diversion and there is no evidence that it causes tolerance,
or either physical or psychological dependence. Human volunteers
with a history of recreational drug or alcohol usage were studied
in two double-blind clinical investigations. None of the subjects
were able to distinguish between BUSPAR and placebo. In addition,
studies in monkeys, mice, and rats have indicated that BUSPAR lacks
potential for abuse.
Although there is no direct evidence that BUSPAR causes physical
dependence or drug-seeking behavior, it is difficult to predict
from experiments the extent to which a CNS-active drug will be misused.
Top
BE SURE TO INCLUDE IN YOUR PHYSCIAL EXAMINATION/MEDICAL QUESTIONAIRRE
FORM THE FOLLOWING INFORMATION:
Include any medications, prescription or non-prescription, alcohol,
or drugs that you are now taking or plan to take during your treatment
with BUSPAR.
Note if you are pregnant, or if you are planning to become pregnant
while you are taking BUSPAR.
Note if you are breast-feeding an infant.
|
